|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy显示文摘Hepatitis due to hepatitis B virus(HBV) reactivation can be severe and potentially fatal, but is preventable. HBV reactivation is most commonly reported in patients receiving cancer chemotherapy, especially rituximabcontaining therapy for hematological malignancies and those receiving stem cell transplantation. All patients with hematological malignancies receiving anticancer therapy should be screened for active or resolved HBV infection by blood tests for hepatitis B surface antigen(HBs Ag) and antibody to hepatitis B core antigen(antiHBc). Patients found to be positive for HBs Ag should be given prophylactic antiviral therapy to prevent HBV reactivation. For patients with resolved HBV infection, no standard strategy has yet been established to prevent HBV reactivation. There are usually two options. One is pre-emptive therapy guided by serial HBV DNA monitoring, whereby antiviral therapy is given as soon as HBV DNA becomes detectable. However, there is little evidence regarding the optimal interval and period of monitoring. An alternative approach is prophylactic antiviral therapy, especially for patients receiving highrisk therapy such as rituximab, newer generation of anti-CD20 monoclonal antibody, obinutuzumab or hematopoietic stem cell transplantation. This strategy may effectively prevent HBV reactivation and avoid the inconvenience of repeated HBV DNA monitoring. Entecavir or tenofovir are preferred over lamivudine as prophylactic therapy. Although there is no well-defined guideline on the optimal duration of prophylactic therapy, there is growing evidence to recommend continuing prophylactic antiviral therapy for at least 12 mo after cessation of chemotherapy, and even longer for those who receive rituximab or who had high serum HBV DNA levels before the start of immunosuppressive therapy. Many novel agents have recently become available for the treatment of hematological malignancies, and these agents may be associated with HBV reactivation. Although there is currently limited evidence to guide the optimal preventive measures, we recommend antiviral prophylaxis in HBs Ag-positive patients receiving novel treatments, especially the Bruton tyrosine kinase inhibitors and the phosphatidylinositol 3-kinase inhibitors, which are B-cell receptor signaling modulators and reduce proliferation of malignant B-cells. Further studies are needed to clarify the risk of HBV reactivation with these agents and the best prophylactic strategy in the era of targeted therapy for hematological malignancies. | Man Fai Law Rita Ho Carmen KM Cheung Lydia HP Tam Karen Ma Kent CY So Bonaventure Ip Jacqueline So Jennifer Lai Joyce Ng Tommy HC Tam | 2016 | World Journal of Gastroenterology2016，22，28： | 10 |
| 2 | Catalytic and regulatiory properties of two forms of bovine heart cyclic nucleotide phosphodiesterase显示文摘 | Ho HC | 1976 | Bochem Biophys Acta1976，429，： | 2 |
| 3 | Intracavernosal injection of vascular endothelial growth factor induces nitric oxide synthase isoforms显示文摘 | Lin CS Ho HC Chen KC | 2002 | BJU Int2002，89，9： | 1 |
| 4 | Genetic analysis of enterovirus 71 iso- lated from fatal and non-fatal cases of hand, foot and mouth disease during an epidemic in Taiwan, 1998 显示文摘 | Shih SR Ho MS Lin KH Wu SL Chen YT Wu CN Lin TY Chang LY Tsao KC Ning HC Chang PY Jung SM Hsueh C Chang KS | 2000 | Virus Res2000，68，2： | 1 |
| 5 | The iliolumbar ligament:a study of its anatomy,development and clinical significance显示文摘 | Luk KD Ho HC Leong JC | 1986 | J Bone Joint Surg Br1986，68，2： | 1 |
| 6 | Causes of venous thrombosis in fifty Chinese patients显示文摘 | Ho CH Chau WK Hsu HC | | 0，，： | 1 |
| 7 | The anti-inflammatory actions of LCY-2-CHO,a carbazole analogue,in vascular smooth muscle cells显示文摘 | Ho FM Kang HC Lee ST | 2007 | Biochem Pharmacol2007，74，2： | 1 |
| 8 | Increased expression and activa- tion of gelatinolytie matrix metalloproteinases is assooiated with the pro_ gression and reeurrenee of human cervical cancer 显示文摘 | Sheu BC Lien HC Ho HN | 2003 | Cancer Res2003，63，19： | 1 |
| 9 | Three-dimension finite analysis of the effects of posts on stress distribution in dentin显示文摘 | Ho MH Lee SY Hsiang HC | 1994 | Prosthet Dent1994，72，： | 1 |
| 10 | Randomized trial of low-dose amiodarone in severe congestive heart failure显示文摘 | Doval HC Nul DR Grancelli HO | 1994 | Lancet1994，344，： | 1 |
| 11 | Three dimensional rendering of the mitochondrial sheath morphogenesis during mouse spermiogenesis 显示文摘 | Ho HC Wey S | 2007 | Microsc Res Tech2007，70，： | 1 |
| 12 | Links ribotyping of vibrio parahaemolyticus isolates obtained from food poisoning outbreaks in Taiwan显示文摘 | Ho CY Kuo LP | 1999 | Microbiol Immunol1999，43，7： | 1 |
| 13 | Correlation of Vascular Endothelial Growth Factor-D Expression and VEGFR-3-Positive Vessel Density with Lymph Node Metastasis in Gastric Carcinoma 显示文摘 | Jung HC Young HO Yong WP | 2008 | J Korean Med Sci2008，23，4： | 1 |
| 14 | Reemerging of enterovirus 71 in Taiwan:the age impact on disease severity显示文摘 | Wang SM Ho TS Lin HC | | 0，，06： | 1 |
| 15 | High JC virus load in gastric cancer and adjacent non-cancerous mucosa显示文摘 | Murai Y Zheng HC Aziz HO | 2007 | Cancer Sci2007，98，1： | 1 |
| 16 | Prognostic influ-ence of parapharyngeal extension in nasopharyngeal car-cinoma显示文摘 | Ho HC Lee MS Hsiao SH | 2008 | Acta Otolaryngol2008，128，： | 1 |
| 17 | Primary tumor volume of nasopharyngeal carcinoma: Significance for survival 显示文摘 | Lee CC Ho HC Lee MS | 2008 | Auris Nasus Larynx2008，35，3： | 1 |
| 18 | Exercise training with negative pressure ventilation improves exercise capacity in patients with severe restrictive lung disease: a prospective controlledstudy显示文摘 | Ho SC Lin HC Kuo HP | 2013 | RespirRes2013，14，1： | 1 |
| 19 | Risk of stroke in patients hospitalizedfor isolated vertigo:a four-year follow-up study显示文摘 | Lee CC Su YC Ho HC | 2011 | Stroke2011，42，： | 1 |
| 20 | Randomized trial of low - dose amiodarone in severe congestive heart failure显示文摘 | Doval HC Nul DR Grancelli HO | 1994 | Lancet1994，344，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员